Literature DB >> 30640063

Generation of an induced pluripotent stem cell line (CSC-46) from a patient with Parkinson's disease carrying a novel p.R301C mutation in the GBA gene.

Nadja Gustavsson1, Ana Marote2, Yuriy Pomeshchik3, Kaspar Russ3, Carla Azevedo3, Margarita Chumarina3, Stefano Goldwurm4, Anna Collin5, Luisa Pinto2, António J Salgado2, Oxana Klementieva1, Laurent Roybon6, Ekaterina Savchenko3.   

Abstract

Mutations in the glucocerebrosidase (GBA) gene have been associated with the development of Parkinson's disease (PD). An induced pluripotent stem cell (iPSC) line was generated from a 60-year old patient diagnosed with PD and carrying a new mutation variant p.R301C in GBA. Using non-integrating Sendai virus-based technology, we utilized OCT3/4, SOX2, c-MYC and KLF4 transcription factors to reprogram skin fibroblasts into iPSCs. The generated iPSC line retained the mutation, displayed expression of common pluripotency markers, differentiated into the three germ layers, and exhibited normal karyotype. The iPSC line can be further used for studying PD pathogenesis.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30640063     DOI: 10.1016/j.scr.2018.101373

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  2 in total

1.  Aberrant proteins expressed in skin fibroblasts of Parkinson's disease patients carrying heterozygous variants of glucocerebrosidase and parkin genes.

Authors:  Phannee Sawangareetrakul; Lukana Ngiwsara; Voraratt Champattanachai; Daranee Chokchaichamnankit; Kittirat Saharat; James R Ketudat Cairns; Chantragan Srisomsap; Kawinthra Khwanraj; Permphan Dharmasaroja; Teeratorn Pulkes; Jisnuson Svasti
Journal:  Biomed Rep       Date:  2021-02-17

2.  The intracellular milieu of Parkinson's disease patient brain cells modulates alpha-synuclein protein aggregation.

Authors:  Nadja Gustavsson; Ekaterina Savchenko; Oxana Klementieva; Laurent Roybon
Journal:  Acta Neuropathol Commun       Date:  2021-09-16       Impact factor: 7.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.